Dishman Carbogen Amcis Q1 Results Total Revenue ₹523.78 Crores & Net Income ₹77.57 Crores

Dishman Carbogen Amcis Growth Comparison 

Dishman Carbogen Amcis Q1 Results: In the first quarter of 2024, Dishman Carbogen Amcis reported several important financial figures in crores. Total revenue was ₹523.78 crores, which shows a significant decline of 20.00% compared to the previous quarter (QoQ), when it was ₹618.56 crores. Year-over-year (YoY), this revenue is down 27.59% from ₹723.38 crores in the same quarter last year. The company's Selling, General, and Administrative (SG&A) expenses totaled ₹316.82 crores, slightly up by 7.35% YoY, although they decreased by 1.23% from the previous quarter.

Dishman Carbogen Amcis’ Total operating expenses reached ₹570.84 crores, a 16.07% decrease QoQ, but down 15.05% YoY compared to ₹671.97 crores last year. Operating income improved from a loss of ₹69.92 crores last quarter to a loss of ₹47.06 crores this quarter. Year-over-year, this is a notable change, but still reflects ongoing challenges. 

Dishman Carbogen Amcis’ net income was negative at ₹77.57 crores, worsening by 10.94% QoQ and significantly down from a profit of ₹17.00 crores last year. The diluted normalized EPS also reflects this trend, showing a loss of ₹4.71 per share. Overall, the YoY results indicate that the company is struggling to recover compared to last year’s performance.

Here’s a simple summary of Dishman Carbogen Amcis' Q1 results:

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 result

Dishman Carbogen Amcis Q1 Results

Dishman Carbogen Amcis reported its unaudited standalone financial results for the quarter ending on June 30, 2024. The total income from operations was 103.41 crores, which shows a decrease compared to 111.26 crores from the previous quarter and an increase from 69.55 crores in the same quarter last year. The company also earned 11.59 crores in other income, resulting in a total income of 115.00 crores. However, the expenses were high, reaching 120.56 crores. These expenses included costs for materials, employee salaries, finance costs, and depreciation, which together significantly impacted the company’s profits.

Before accounting for taxes, Dishman Carbogen Amcis faced a loss of 5.56 crores. After considering taxes, which included current and deferred taxes, the final net loss after tax for the quarter was 3.47 crores. This shows that while the company is generating some income, the costs are outpacing revenue, leading to a loss. Overall, the results highlight the challenges the company is facing in terms of managing expenses while trying to grow its income. Understanding these numbers helps investors see how well the company is doing financially and what areas may need improvement.

Here’s a summary of the unaudited standalone results for Dishman Carbogen Amcis for the quarter ended June 30, 2024:

(Rupees in Crores)

Dishman Carbogen Amcis Stock Performance

Dishman Carbogen Amcis is a company with a market cap of ₹ 2,957 crore, meaning this is its total value on the stock market. The current stock price is ₹ 189, with a high of ₹ 283 and a low of ₹ 133 over a certain period. The book value, which indicates the company's net worth per share, is ₹ 359. However, the company does not pay any dividends, reflected in a 0.00% yield. Its return on capital employed (ROCE) is low at 0.02%, and its return on equity (ROE) is negative at -2.64%, suggesting financial challenges.

Here’s the information you provided in a simple table format:

Quarterly Results 

In the table for Dishman Carbogen Amcis, the data for December 2023, March 2024, and June 2024 shows a challenging financial situation. In December 2023, the company had sales of 651 crores, but this slightly increased to 655 crores in March 2024 before dropping significantly to 524 crores by June 2024. Expenses were high, reaching 610 crores in December and slightly decreasing to 495 crores in June. 

Here’s the summary for Dec 2023, Mar 2024, and Jun 2024:

About Dishman Carbogen Amcis

Dishman Carbogen Amcis has been supporting the pharmaceutical and healthcare industries for over 30 years. They focus on helping clients develop new drugs and bring them to market. The company is dedicated to improving the lives of patients around the world by providing high-quality services in drug development and manufacturing.

Dishman Carbogen Amcis's vision is to be the preferred partner for creating complex and challenging substances, including potent active ingredients and innovative healthcare products. They aim to support their customers in making a better world through their work.

Dishman Carbogen Amcis prioritizes client satisfaction by reducing risks and time involved in drug development. They offer long-term solutions for contract manufacturing, ensuring that their clients receive reliable and valuable support. The company is committed to excellence and innovation, making it a trusted name in the industry.

With a strong leadership team and a focus on operational efficiency, Dishman Carbogen Amcis continues to play a vital role in the advancement of healthcare, helping to develop effective treatments for various diseases and conditions. Their commitment to quality and client care makes them a key player in the pharmaceutical field.